The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.
What Happened: The U.S. is set to impose a 15% tariff on branded drugs imported from Europe, reported Axios. This move could result in billions of dollars in additional expenses for the pharmaceutical companies, potentially leading to increased drug prices and limited access for consumers.
